BR112017020502A2 - proteínas de fusão - Google Patents

proteínas de fusão

Info

Publication number
BR112017020502A2
BR112017020502A2 BR112017020502-5A BR112017020502A BR112017020502A2 BR 112017020502 A2 BR112017020502 A2 BR 112017020502A2 BR 112017020502 A BR112017020502 A BR 112017020502A BR 112017020502 A2 BR112017020502 A2 BR 112017020502A2
Authority
BR
Brazil
Prior art keywords
fusion proteins
present
time
extended
diabetes
Prior art date
Application number
BR112017020502-5A
Other languages
English (en)
Inventor
Bruce Baldwin David
Michael Beals John
Wesley Day Jonathan
Duane Dickinson Craig
Ihor Korytko Andrew
Alan Lazar Gregory
Original Assignee
Eli Lilly And Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55953435&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112017020502(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Eli Lilly And Company filed Critical Eli Lilly And Company
Publication of BR112017020502A2 publication Critical patent/BR112017020502A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)

Abstract

a presente invenção refere-se a proteínas de fusão compreendendo um agonista de receptor de insulina fundido a uma região fc de igg humana através do uso de um ligante de peptídeo e ao uso de tais proteínas de fusão no tratamento de diabetes. a proteína de fusão da presente invenção tem um perfil de ação de tempo prolongado e é útil para provisão de controle de glicose basal por um período de tempo prolongado.
BR112017020502-5A 2015-05-07 2016-04-28 proteínas de fusão BR112017020502A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562158079P 2015-05-07 2015-05-07
US62/158,079 2015-05-07
PCT/US2016/029807 WO2016178905A1 (en) 2015-05-07 2016-04-28 Fusion proteins

Publications (1)

Publication Number Publication Date
BR112017020502A2 true BR112017020502A2 (pt) 2018-07-03

Family

ID=55953435

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017020502-5A BR112017020502A2 (pt) 2015-05-07 2016-04-28 proteínas de fusão

Country Status (42)

Country Link
US (4) US9855318B2 (pt)
EP (1) EP3292141B1 (pt)
JP (1) JP6591562B2 (pt)
KR (1) KR102059736B1 (pt)
CN (1) CN107531806B (pt)
AR (1) AR105616A1 (pt)
AU (1) AU2016257659B2 (pt)
BR (1) BR112017020502A2 (pt)
CA (1) CA2981102A1 (pt)
CL (1) CL2017002761A1 (pt)
CO (1) CO2017011301A2 (pt)
CR (1) CR20170469A (pt)
CY (1) CY1122929T1 (pt)
DK (1) DK3292141T3 (pt)
DO (1) DOP2017000258A (pt)
EA (1) EA039770B1 (pt)
EC (1) ECSP17073650A (pt)
ES (1) ES2799099T3 (pt)
HK (1) HK1244019A1 (pt)
HR (1) HRP20200503T1 (pt)
IL (1) IL254965B (pt)
JO (1) JO3658B1 (pt)
LT (1) LT3292141T (pt)
MA (1) MA42037B1 (pt)
MD (1) MD3292141T2 (pt)
ME (1) ME03709B (pt)
MX (1) MX2017014284A (pt)
MY (1) MY183025A (pt)
NZ (1) NZ736470A (pt)
PE (1) PE20180507A1 (pt)
PH (1) PH12017502025A1 (pt)
PL (1) PL3292141T3 (pt)
PT (1) PT3292141T (pt)
RS (1) RS60044B1 (pt)
SG (1) SG11201708194WA (pt)
SI (1) SI3292141T1 (pt)
SV (1) SV2017005548A (pt)
TN (1) TN2018000059A1 (pt)
TW (1) TWI656132B (pt)
UA (1) UA122146C2 (pt)
WO (1) WO2016178905A1 (pt)
ZA (1) ZA201706334B (pt)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6983075B2 (ja) 2015-06-02 2021-12-17 ノヴォ ノルディスク アー／エス 極性の組換え延長部を有するインスリン
MA43348A (fr) 2015-10-01 2018-08-08 Novo Nordisk As Conjugués de protéines
CA3030544A1 (en) 2016-07-27 2018-02-01 Hewlett-Packard Development Company, L.P. Horizontal interface for fluid supply cartridge having digital fluid level sensor
CA3046337C (en) * 2016-12-09 2021-06-01 Akston Biosciences Corporation Insulin-fc fusions and methods of use
TR201703622A1 (tr) * 2017-03-09 2018-09-21 Univ Yeditepe Obezi̇te tedavi̇si̇ i̇çi̇n bi̇r ürün
EP3606560A2 (en) 2017-04-05 2020-02-12 Novo Nordisk A/S Oligomer extended insulin-fc conjugates
CN112739713A (zh) 2018-06-25 2021-04-30 华盛顿大学 有力的且选择性的白介素模拟物的从头设计
EP3655006B1 (en) 2018-06-29 2021-11-17 Akston Biosciences Corporation Ultra-long acting insulin-fc fusion proteins and methods of use
US11267862B2 (en) 2018-06-29 2022-03-08 Akston Biosciences Corporation Ultra-long acting insulin-Fc fusion proteins and methods of use
EP3863680A1 (en) 2018-10-10 2021-08-18 Novo Nordisk A/S Oligomer extended insulin-fc conjugates and their medical use
AU2019384523A1 (en) 2018-11-20 2021-04-22 University Of Washington Split interleukin mimetics and their use
WO2021011827A1 (en) * 2019-07-16 2021-01-21 Akston Biosciences Corporation Ultra-long acting insulin-fc fusion proteins and methods of use
TW202120536A (zh) 2019-07-31 2021-06-01 美商美國禮來大藥廠 鬆弛素(relaxin)類似物及其使用方法
WO2021076620A1 (en) 2019-10-15 2021-04-22 Eli Lilly And Company Recombinantly engineered, lipase/esterase-deficient mammalian cell lines
US11352407B2 (en) * 2019-12-19 2022-06-07 Akston Biosciences Corporation Ultra-long acting insulin-Fc fusion proteins
US11186623B2 (en) 2019-12-24 2021-11-30 Akston Bioscience Corporation Ultra-long acting insulin-Fc fusion proteins and methods of use
WO2021188374A2 (en) 2020-03-16 2021-09-23 Neoleukin Therapeutics, Inc. Interleukin-2 receptor βeta (il-2rβ) binding polypeptides
EP4132964A2 (en) 2020-04-07 2023-02-15 Neoleukin Therapeutics, Inc. De novo protein decoys of angiotensin-converting enzyme 2 (ace2)
FI3972987T3 (fi) 2020-04-10 2023-07-25 Akston Biosciences Corp Antigeenispesifinen immunoterapia COVID-19-fuusioproteiineille ja sen käyttömenetelmät
US11192930B2 (en) 2020-04-10 2021-12-07 Askton Bioscences Corporation Ultra-long acting insulin-Fc fusion protein and methods of use
US11198719B2 (en) 2020-04-29 2021-12-14 Akston Biosciences Corporation Ultra-long acting insulin-Fc fusion protein and methods of use
KR20230118648A (ko) * 2020-12-14 2023-08-11 일라이 릴리 앤드 캄파니 당뇨병을 치료하는 방법
WO2023004406A2 (en) 2021-07-23 2023-01-26 Akston Biosciences Corporation Insulin-fc fusion proteins and methods of use to treat cancer
WO2023044318A2 (en) 2021-09-15 2023-03-23 Neoleukin Therapeutics, Inc. Interleukin-2 receptor βeta (il-2rβ) binding polypeptides
AR127619A1 (es) 2021-11-15 2024-02-14 Lilly Co Eli FORMULACIONES CONSERVADAS DE FUSIONES DE INSULINA-Fc
WO2023174370A1 (zh) * 2022-03-16 2023-09-21 北京拓界生物医药科技有限公司 人胰岛素类似物、其融合蛋白及医药用途
WO2023225534A1 (en) 2022-05-18 2023-11-23 Protomer Technologies Inc. Aromatic boron-containing compounds and related insulin analogs
WO2023247640A1 (en) 2022-06-23 2023-12-28 Sanofi Single chain insulins and fc conjugates thereof

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US5120712A (en) 1986-05-05 1992-06-09 The General Hospital Corporation Insulinotropic hormone
US5514646A (en) 1989-02-09 1996-05-07 Chance; Ronald E. Insulin analogs modified at position 29 of the B chain
HU225496B1 (en) 1993-04-07 2007-01-29 Scios Inc Pharmaceutical compositions of prolonged delivery, containing peptides
US5424286A (en) 1993-05-24 1995-06-13 Eng; John Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same
IL118127A0 (en) 1995-05-05 1996-09-12 Lilly Co Eli Single chain insulin with high bioactivity
US6268343B1 (en) 1996-08-30 2001-07-31 Novo Nordisk A/S Derivatives of GLP-1 analogs
WO2001000223A2 (en) 1999-06-25 2001-01-04 Minimed Inc. Multiple agent diabetes therapy
KR100449454B1 (ko) 2000-10-02 2004-09-21 이현철 단일사슬 인슐린 유도체의 유전자를 포함하는 당뇨병치료용 벡터
CZ308214B6 (cs) 2000-12-07 2020-03-04 Eli Lilly And Company GLP-1 fúzní proteiny
SK2432004A3 (sk) 2001-12-20 2005-04-01 Eli Lilly And Company Inzulínová zlúčenina s protrahovaným účinkom
KR100758755B1 (ko) * 2003-06-12 2007-09-14 일라이 릴리 앤드 캄파니 Ｇｌｐ-1 유사체 융합 단백질
DE60333600D1 (de) 2003-10-02 2010-09-09 Zeiss Carl Smt Ag Projektionsobjektiv für die halbleiter-lithographie
JP5697831B2 (ja) 2003-12-03 2015-04-08 ノヴォ ノルディスク アー／エス 単鎖インシュリン
EP1863840A1 (en) 2005-03-18 2007-12-12 Novo Nordisk A/S Pegylated single-chain insulin
EP1991575A1 (en) 2006-02-21 2008-11-19 Novo Nordisk A/S Single-chain insulin analogues and pharmaceutical formulations thereof
EP1996223A1 (en) 2006-03-13 2008-12-03 Novo Nordisk A/S Acylated single chain insulin
JP2009530243A (ja) 2006-03-13 2009-08-27 ノボ・ノルデイスク・エー／エス アシル化単鎖インスリン
EP2404934A1 (en) 2006-09-22 2012-01-11 Novo Nordisk A/S Protease resistant insulin analogues
EP2074140B8 (en) 2006-10-04 2015-10-28 Case Western Reserve University Fibrillation-resistant insulin and insulin analogues
WO2008049711A1 (en) 2006-10-27 2008-05-02 Novo Nordisk A/S Peptide extended insulins
EP2162472B1 (en) * 2007-05-30 2013-02-27 Postech Academy-Industry- Foundation Immunoglobulin fusion proteins
JP2010533197A (ja) 2007-07-10 2010-10-21 イーライ リリー アンド カンパニー ＧＬＰ−１−Ｆｃ融合タンパク質配合物
WO2009112583A2 (en) 2008-03-14 2009-09-17 Novo Nordisk A/S Protease-stabilized insulin analogues
AU2009226910B2 (en) * 2008-03-18 2014-02-06 Novo Nordisk A/S Protease stabilized, acylated insulin analogues
BRPI0911571A2 (pt) 2008-04-22 2018-04-03 Univ Case Western Reserve método para tratar um mamífero, análogo de insulina, ácido nucléico e célula hospedeira
GB0812019D0 (en) 2008-07-02 2008-08-06 Asterion Ltd Insulin
WO2010011096A2 (en) 2008-07-23 2010-01-28 Hanmi Pharmaceutical Co., Ltd. A polypeptide complex comprising non-peptidyl polymer having three functional ends
AR081066A1 (es) 2010-04-02 2012-06-06 Hanmi Holdings Co Ltd Conjugado de insulina donde se usa un fragmento de inmunoglobulina
KR101324828B1 (ko) * 2010-06-08 2013-11-01 한미사이언스 주식회사 면역글로불린 단편을 이용한 단쇄 인슐린 아날로그 약물 결합체
WO2011159895A2 (en) 2010-06-16 2011-12-22 Indiana University Research And Technology Corporation Single chain insulin agonists exhibiting high activity at the insulin receptor
CA2827033A1 (en) 2011-02-09 2012-08-16 Glaxosmithkline Llc Lyophilized formulations
CN102718870B (zh) * 2011-05-24 2014-04-30 马鞍山中美德康生物科技有限公司 一种胰岛素生物增敏剂及其应用
UA113626C2 (xx) 2011-06-02 2017-02-27 Композиція для лікування діабету, що містить кон'югат інсуліну тривалої дії та кон'югат інсулінотропного пептиду тривалої дії
CN102516393B (zh) * 2011-11-30 2017-03-15 北京康明百奥新药研发有限公司 胰岛素模拟肽融合蛋白和突变体及其应用
CN103509118B (zh) * 2012-06-15 2016-03-23 郭怀祖 胰岛素-Fc融合蛋白
WO2014009316A1 (en) 2012-07-09 2014-01-16 Novo Nordisk A/S Novel use of insulin derivatives
AR091902A1 (es) 2012-07-25 2015-03-11 Hanmi Pharm Ind Co Ltd Formulacion liquida de un conjugado de insulina de accion prolongada
AR092862A1 (es) 2012-07-25 2015-05-06 Hanmi Pharm Ind Co Ltd Formulacion liquida de insulina de accion prolongada y un peptido insulinotropico y metodo de preparacion
JP6387008B2 (ja) 2012-09-26 2018-09-05 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションＩｎｄｉａｎａ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ インスリンアナローグダイマー
EP2914620B1 (en) 2012-11-05 2018-08-08 Case Western Reserve University Long-acting single-chain insulin analogues
EP2963055B1 (en) 2013-02-26 2019-05-15 Hanmi Pharm. Co., Ltd. Site-specific insulin conjugate
EA201591700A1 (ru) * 2013-03-14 2015-12-30 Ридженерон Фармасьютикалз, Инк. Гибридные белки апелина и их применение
JP6499184B2 (ja) 2013-10-07 2019-04-10 ノヴォ ノルディスク アー／エス インスリン類似体の新規な誘導体
EP3098235A4 (en) 2014-01-20 2017-10-18 Hanmi Pharm. Co., Ltd. Long-acting insulin and use thereof
AR100639A1 (es) 2014-05-29 2016-10-19 Hanmi Pharm Ind Co Ltd Composición para tratar diabetes que comprende conjugados de análogos de insulina de acción prolongada y conjugados de péptidos insulinotrópicos de acción prolongada
TWI684458B (zh) 2014-05-30 2020-02-11 南韓商韓美藥品股份有限公司 包含胰島素及ｇｌｐ-１/昇糖素雙重促效劑之治療糖尿病之組成物
KR20160001391A (ko) 2014-06-27 2016-01-06 한미약품 주식회사 신규한 지속형 인슐린 아날로그 결합체 및 이의 용도
KR20160007295A (ko) 2014-07-11 2016-01-20 한미약품 주식회사 인슐린 아날로그
KR102569743B1 (ko) 2014-10-06 2023-08-23 케이스 웨스턴 리저브 유니버시티 이상 단일 사슬 인슐린 유사체
CR20170208A (es) 2014-11-21 2017-07-17 Merck Sharp & Dohme Agonistas parciales del receptor de insulina
CN107810202A (zh) 2015-02-17 2018-03-16 韩美药品株式会社 长效胰岛素或胰岛素类似物复合物
CN110134210A (zh) 2019-04-16 2019-08-16 深圳市国鑫恒宇科技有限公司 一种服务器一体机的温度控制方法、系统、装置及存储介质

Also Published As

Publication number Publication date
TN2018000059A1 (en) 2019-07-08
PH12017502025B1 (en) 2018-04-02
DOP2017000258A (es) 2017-12-31
US20200390865A1 (en) 2020-12-17
ES2799099T3 (es) 2020-12-14
CA2981102A1 (en) 2016-11-10
TW201712029A (zh) 2017-04-01
US20180177851A1 (en) 2018-06-28
DK3292141T3 (da) 2020-04-20
ECSP17073650A (es) 2018-02-28
CN107531806A (zh) 2018-01-02
PL3292141T3 (pl) 2020-06-29
US20220211818A1 (en) 2022-07-07
RS60044B1 (sr) 2020-04-30
ZA201706334B (en) 2020-01-29
MY183025A (en) 2021-02-07
WO2016178905A1 (en) 2016-11-10
HK1244019A1 (zh) 2018-07-27
EP3292141B1 (en) 2020-02-12
MD3292141T2 (ro) 2020-07-31
CO2017011301A2 (es) 2018-03-20
MX2017014284A (es) 2018-03-23
US9855318B2 (en) 2018-01-02
KR102059736B1 (ko) 2019-12-26
JO3658B1 (ar) 2020-08-27
SV2017005548A (es) 2018-04-24
CR20170469A (es) 2017-11-14
JP6591562B2 (ja) 2019-10-16
PE20180507A1 (es) 2018-03-09
CY1122929T1 (el) 2021-10-29
ME03709B (me) 2021-01-20
UA122146C2 (uk) 2020-09-25
JP2018515088A (ja) 2018-06-14
CL2017002761A1 (es) 2018-05-18
HRP20200503T1 (hr) 2020-06-26
EP3292141A1 (en) 2018-03-14
AU2016257659B2 (en) 2018-08-09
PH12017502025A1 (en) 2018-04-02
PT3292141T (pt) 2020-04-22
SG11201708194WA (en) 2017-11-29
CN107531806B (zh) 2022-06-07
IL254965B (en) 2021-03-25
EA039770B1 (ru) 2022-03-11
NZ736470A (en) 2019-04-26
TWI656132B (zh) 2019-04-11
US10709766B2 (en) 2020-07-14
AR105616A1 (es) 2017-10-25
LT3292141T (lt) 2020-03-25
MA42037B1 (fr) 2020-03-31
AU2016257659A1 (en) 2017-10-12
IL254965A0 (en) 2017-12-31
US20160324932A1 (en) 2016-11-10
EA201792199A1 (ru) 2018-03-30
US11253574B2 (en) 2022-02-22
KR20170134614A (ko) 2017-12-06
SI3292141T1 (sl) 2020-04-30

Similar Documents

Publication Publication Date Title
BR112017020502A2 (pt) proteínas de fusão
PH12020550205A1 (en) IL-22 POLYPEPTIDES AND IL-22 Fc FUSION PROTEINS AND METHODS OF USE
EA201790063A1 (ru) Слитые белки интерлейкин-2/рецептор интерлейкина-2 альфа и способы применения
BR112018073511A2 (pt) polipeptídeos seletivos do receptor de glucagon e métodos de uso dos mesmos
CY1122539T1 (el) Αναλογα γλυκαγονης
CY1121462T1 (el) Ακυλιωμενα αναλογα γλυκαγονης
GEP20217326B (en) Constructs having a sirp-alpha domain or variant thereof
BR112017008157A2 (pt) polipeptídeos de fgf-21 modificados e usos dos mesmos
BR112017006178A2 (pt) região fc, anticorpos, formulação farmacêutica e usos dos anticorpos
BR112016013187A2 (pt) receptores de antígenos quiméricos de mesotelina humanos e usos dos mesmos
CL2018002494A1 (es) Péptidos, ácidos nucleicos, vectores de expresión y células para la utilización de inmunoterapia contra el cáncer (divisional solicitud 201600227)
PE20170142A1 (es) Proteina de fusion que inhibe angiogenesis o crecimiento y uso de la misma
CL2019001586A1 (es) Insulina que contiene composiciones farmacéuticas.
BR112016002572A2 (pt) peptídeos
PE20160723A1 (es) Glicoproteinas recombinantes y sus usos
EA202090582A3 (ru) Полипептиды il-22, химерные белки il-22 fc и их применение
AR099080A1 (es) Variantes de región fc con propiedades de unión a fcrn (receptor fc neonatal) modificadas y de unión a proteína a mantenidas
EA201992746A3 (ru) Рекомбинантные гликопротеиды и их применения
AR095528A1 (es) Polipéptidos de interleucina-22 (il-22) y proteínas de fusión de il-22 con fragmento de cadena pesada fc (il-22 fc) y métodos de uso

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]